Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Therapy of HES, PV, Atypical CML or CMML, and Mastocytosis With Imatinib Mesylate
This study is ongoing, but not recruiting participants.
Study NCT00038675 Information provided by M.D. Anderson Cancer Center
First Received: June 4, 2002 Last Updated: April 21, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Myelomonocytic Leukemia
Chronic Myeloid Leukemia
Polycythemia Vera
Hypereosinophilic Syndrome
Mastocytosis
Additional conditions recognized in this trial
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Mastocytoma
Polycythemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Eosinophilia
Hematologic Diseases
Leukocyte Disorders
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Connective Tissue
Pathologic Processes
Skin Diseases
Interventions listed in this trial
Imatinib Mesylate (Gleevec)
Additional drug interventions recognized in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Novartis Pharmaceuticals
Back to top of Main Content
